Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.
AUTOR(ES)
Hasenkrug, K J
RESUMO
Administration of virus-specific antibodies is known to be an effective early treatment for some viral infections. Such immunotherapy probably acts by antibody-mediated neutralization of viral infectivity and is often thought to function independently of T-cell-mediated immune responses. In the present experiments, we studied passive antibody therapy using Friend murine leukemia virus complex as a model for an immunosuppressive retroviral disease in adult mice. The results showed that antibody therapy could induce recovery from a well-established retroviral infection. However, the success of therapy was dependent on the presence of both CD4+ and CD8+ T lymphocytes. Thus, cell-mediated responses were required for recovery from infection even in the presence of therapeutic levels of antibody. The major histocompatibility type of the mice was also an important factor determining the relative success of antibody therapy in this system, but it was less critical for low-dose than for high-dose infections. Our results imply that limited T-cell responsiveness as dictated by major histocompatibility genes and/or stage of disease may have contributed to previous immunotherapy failures in AIDS patients. Possible strategies to improve the efficacy of future therapies are discussed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=40637Documentos Relacionados
- Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness.
- Restricted and conserved T-cell repertoires involved in allorecognition of class II major histocompatibility complex.
- Predictions of T-cell receptor- and major histocompatibility complex-binding sites on staphylococcal enterotoxin C1.
- Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs.
- Binding of a soluble alpha beta T-cell receptor to superantigen/major histocompatibility complex ligands.
